

Rosmawati Mohamed

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1242476/publications.pdf>

Version: 2024-02-01

44
papers

1,733
citations

516215

16
h-index

276539

41
g-index

46
all docs

46
docs citations

46
times ranked

2576
citing authors

#	ARTICLE	IF	CITATIONS
1	Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A large-scale Asian study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 156-170.	1.0	6
2	Primer and probe conservation issue in the quantification of hepatitis B virus DNA. <i>Reviews in Medical Virology</i> , 2021, 31, e2182.	3.9	1
3	Hepatitis C virus core antigen as alternative diagnostic algorithm for active hepatitis C virus infection among haemodialysis population: Cost implications. <i>Nephrology</i> , 2021, 26, 463-470.	0.7	1
4	Association of deleted in liver cancer-1 gene polymorphism with increased risk of chronicity of disease among Malaysian patients with hepatitis B infection. <i>Pharmacogenetics and Genomics</i> , 2021, Publish Ahead of Print, 185-190.	0.7	0
5	Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 486-498.	4.5	20
6	Risk factors of nonalcoholic fatty liver disease in lean body mass population: A systematic review and meta-analysis. <i>JGH Open</i> , 2021, 5, 1236-1249.	0.7	11
7	Comparative expression of pro-inflammatory and apoptotic biosignatures in chronic HBV-infected patients with and without liver cirrhosis. <i>Microbial Pathogenesis</i> , 2021, 161, 105231.	1.3	9
8	MAIT cells in hepatitis B virus infection – Diplomatic front-runners in the fight against HBV disease. <i>Critical Reviews in Immunology</i> , 2021, 41, 1-16.	1.0	1
9	Asian consensus recommendations on optimizing the diagnosis and initiation of treatment of hepatitis B virus infection in resource-limited settings. <i>Journal of Viral Hepatitis</i> , 2020, 27, 466-475.	1.0	8
10	Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1297-1305.	1.0	19
11	An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. <i>Journal of Gastroenterology</i> , 2020, 55, 811-823.	2.3	41
12	Hepatitis C core antigen testing to diagnose active hepatitis C infection among haemodialysis patients. <i>BMC Nephrology</i> , 2020, 21, 480.	0.8	6
13	Allele HLA-DQB1*06 reduces fibrosis score in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2020, 50, 947-954.	1.8	0
14	2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. <i>Kidney International Reports</i> , 2020, 5, 1129-1138.	0.4	14
15	Estimating the Population Size of People Who Inject Drugs in Malaysia for 2014 and 2017 Using the Benchmark-Multiplier Method. <i>Substance Use and Misuse</i> , 2020, 55, 871-877.	0.7	4
16	Increased Coffee Intake Reduces Circulating HBV DNA and HBsAg Levels in HBeAg-Negative Infection: A Cohort Study. <i>Viruses</i> , 2019, 11, 808.	1.5	3
17	A Stepwise Approach to a National Hepatitis C Screening Strategy in Malaysia to Meet the WHO 2030 Targets: Proposed Strategy, Coverage, and Costs. <i>Value in Health Regional Issues</i> , 2019, 18, 112-120.	0.5	18
18	Metabolic Syndrome Is Associated With Advanced Liver Fibrosis Among Pediatric Patients With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Pediatrics</i> , 2019, 7, 491.	0.9	20

#	ARTICLE	IF	CITATIONS
19	Sofosbuvir+velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 127-134.	3.7	83
20	Hepatitis C elimination by 2030 in Malaysia: an achievable goal?. <i>Journal of Virus Eradication</i> , 2019, 5, 253.	0.3	1
21	IDDF2018-ABS-0112...Safety and efficacy of sofosbuvir/velpatasvir in a genotype 1 hcv infected population from singapore, malaysia, thailand, and vietnam: results from a phase 3, clinical trial. , 2018, , .		2
22	Hepatocellular Carcinoma in Malaysia and Its Changing Trend. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2018, 8, 54-56.	0.1	12
23	Interleukin-6 gene variants are associated with reduced risk of chronicity in hepatitis B virus infection in a Malaysian population. <i>Biomedical Reports</i> , 2018, 9, 213-220.	0.9	13
24	Viral Persistence and Chronicity in Hepatitis C Virus Infection: Role of T-Cell Apoptosis, Senescence and Exhaustion. <i>Cells</i> , 2018, 7, 165.	1.8	27
25	Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018-2040. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 847-857.	1.0	11
26	Hepatitis Screening and Treatment Campaign in Malaysia- Validation of Low-cost Point of Care Screening Tests and Nucleic Acid Tests for Hepatitis B and C. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2018, 8, 101-107.	0.1	7
27	CD8+ T cells of chronic HCV-infected patients express multiple negative immune checkpoints following stimulation with HCV peptides. <i>Cellular Immunology</i> , 2017, 313, 1-9.	1.4	22
28	Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2017, 50, 161-166.	0.4	14
29	Novel Genetic Variants of Hepatitis B Virus in Fulminant Hepatitis. <i>Journal of Pathogens</i> , 2017, 2017, 1-6.	0.9	6
30	Chronic Viral Hepatitis in Malaysia: "Where are we now?". <i>Euroasian Journal of Hepato-gastroenterology</i> , 2017, 7, 65-67.	0.1	4
31	Peripheral loss of CD ⁸ CD ¹⁶¹ TCRV ^{±7.2} mucosal-associated invariant T cells in chronic hepatitis C virus-infected patients. <i>European Journal of Clinical Investigation</i> . 2016. 46. 170-180.	1.7	75
32	Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 248-255.	3.7	54
33	Conflicting reports on the role of the glyceimic effect of <i>Catha edulis</i> (Khat): A systematic review and meta-analysis. <i>Journal of Ethnopharmacology</i> , 2016, 186, 30-43.	2.0	12
34	Copy number variation in exportin-4 (XPO4) gene and its association with histological severity of non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2015, 5, 13306.	1.6	6
35	Universal Primers for Detection and Sequencing of Hepatitis B Virus Genomes across Genotypes A to G. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1831-1835.	1.8	21
36	Projections of the Current and Future Disease Burden of Hepatitis C Virus Infection in Malaysia. <i>PLoS ONE</i> , 2015, 10, e0128091.	1.1	21

#	ARTICLE	IF	CITATIONS
37	Bridging the data gaps in the epidemiology of hepatitis C virus infection in Malaysia using multi-parameter evidence synthesis. BMC Infectious Diseases, 2014, 14, 564.	1.3	31
38	Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: A randomized trial. Journal of Clinical Virology, 2014, 61, 509-516.	1.6	14
39	Genome-Wide Analysis of Copy Number Variation Identifies Candidate Gene Loci Associated with the Progression of Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e95604.	1.1	30
40	Stopping Therapy in HBeAg Negative Disease. Current Hepatitis Reports, 2013, 12, 105-111.	0.3	1
41	Knowledge, attitudes and practices among people with chronic hepatitis B attending a hepatology clinic in Malaysia: A cross sectional study. BMC Public Health, 2012, 12, 601.	1.2	45
42	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatology International, 2012, 6, 531-561.	1.9	874
43	A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. Human Genetics, 2012, 131, 1145-1152.	1.8	84
44	Practical difficulties in the management of hepatitis B in the Asia-Pacific region. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 958-969.	1.4	51